Cue Biopharma Inc (NAS:CUE)
$ 1.72 -0.06 (-3.37%) Market Cap: 103.56 Mil Enterprise Value: 84.79 Mil PE Ratio: 0 PB Ratio: 3.87 GF Score: 64/100

Cue Biopharma Inc at Cowen Healthcare Conference (Virtual) Transcript

Mar 04, 2021 / 02:10PM GMT
Release Date Price: $12.26 (-1.61%)
Shau;Wei Chen
Cowen and Company, LLC, Research Division - Research Associate

Good morning. My name is Cynthia, and I'm a member of the biotech team. It's my pleasure to introduce Dan Passeri, the CEO of Cue Biopharma.

Daniel R. Passeri
Cue Biopharma, Inc. - CEO & Director

Thank you very much. Good morning, everyone. First, I want to thank Cowen for giving us an opportunity to present at their conference.

So Cue is an immunotherapy company dedicated to protein engineering for immune modulation. Our symbol -- NASDAQ symbol is CUE. Just as a reminder, this presentation is being webcast and will be on our web for 30 days after this conference that you can listen to. I'll also reference when -- what slide I'm on.

So next slide is forward-looking statements. This presentation may contain some forward-looking statements.

Now Slide #3. Cue is dedicated to rationally engineering biologics in therapeutics, in essence, harness nature's cues for selective and specific immune modulation. And next couple of slides will be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot